How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 29 Mar | 06 Apr | 04 May | 26 Jun | 06 Jul | 11 Jul | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 58.6 | 58.6 | 59.7 | 60.1 | 60.1 | 60.1 | +1.5 |
| Healthcare | 38.0 | 38.0 | 36.1 | 34.6 | 34.6 | 34.6 | -3.5 |
| Financial Services | 1.3 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | +0.1 |
| Digital | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | +0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 8.68% | 10 | 8 | 6 | 4 | 2 | 1/2 | +13.9% |
| APOLLOHOSP | Healthcare | 8.68% | 10 | 5 | 7 | 2 | 2 | 0/2 | +14.5% |
| CIPLA | Pharma | 6.76% | 6 | 3 | 5 | 3 | 6 | 0/2 | +13.9% |
| DIVISLAB | Pharma | 6.43% | 10 | 8 | 1 | 6 | 1 | 1/2 | +8.1% |
| MAXHEALTH | Healthcare | 6.29% | 7 | 9 | 5 | 4 | 3 | 0/2 | +12.2% |
| DRREDDY | Pharma | 5.03% | 7 | 2 | 5 | 1 | 7 | 0/2 | -0.3% |
| JBCHEPHARM | Pharma | 4.53% | 9 | 7 | 2 | 5 | 1 | 1/2 | +18.6% |
| GLENMARK | Pharma | 3.66% | 6 | 9 | 10 | 4 | 3 | 0/2 | +1.5% |
| LALPATHLAB | Healthcare | 3.00% | 10 | 8 | 7 | 1 | 3 | 0/2 | +16.6% |
| AJANTPHARM | Pharma | 2.83% | 8 | 10 | 1 | 4 | 3 | 0/2 | +14.6% |
| ZYDUSLIFE | Pharma | 2.77% | 10 | 10 | 10 | 10 | 6 | 1/2 | +23.3% |
| AUROPHARMA | Pharma | 2.75% | 9 | 3 | 10 | 6 | 6 | 0/2 | +14.4% |
| MEDANTA | Healthcare | 2.68% | 9 | 9 | 6 | 8 | 2 | 0/2 | +23.2% |
| RAINBOW | Healthcare | 2.22% | 10 | 7 | 2 | 5 | 4 | 1/2 | +15.3% |
| ERIS | Pharma | 2.04% | 5 | 7 | 5 | 6 | 6 | 0/2 | +1.0% |
| PFIZER | Healthcare | 1.92% | 3 | 7 | 1 | 2 | 7 | 0/2 | -9.0% |
| MANKIND | Pharma | 1.91% | 10 | 8 | 9 | 5 | 2 | 0/2 | +18.5% |
| ABBOTINDIA | Pharma | 1.90% | 4 | 9 | — | 8 | 7 | 0/2 | +0.6% |
| SYNGENE | Healthcare | 1.85% | 2 | 3 | 6 | 9 | 7 | 0/2 | -0.6% |
| GLAXO | Healthcare | 1.78% | 6 | 7 | 2 | 6 | 7 | 0/2 | +1.2% |
| IPCALAB | Pharma | 1.72% | 10 | 6 | 1 | 8 | 4 | 1/2 | +18.3% |
| LUPIN | Pharma | 1.64% | 10 | 10 | 10 | 6 | 7 | 1/2 | +4.0% |
| NH | Healthcare | 1.52% | 9 | 8 | 8 | 2 | 3 | 0/2 | +10.3% |
| STARHEALTH | Financial Services | 1.36% | 10 | — | 7 | 1 | 1 | 0/2 | +25.2% |
| SAILIFE | Healthcare | 1.12% | 8 | 9 | 6 | 5 | 2 | 0/2 | +20.3% |
| CONCORDBIO | Pharma | 0.68% | 5 | 4 | 2 | 1 | 4 | 0/2 | +19.8% |
| IKS | Digital | 0.27% | 9 | 10 | 10 | 9 | 1 | 0/2 | +17.7% |
Performance · 0.6y
Over the last 0.6 years ₹100 in the fund grew to ₹109 (+9%), vs ₹96 for Nifty 500 (−4%) and ₹92 for Nifty 50 (−8%). Its relative-strength line ended at 119 vs Nifty 50 and 113 vs Nifty 500 — above 100, sustained outperformance.